You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

The Nurse View: Incorporating PARP Inhibitor Therapy in Advanced Ovarian Cancer Management

  • Authors: Paula Anastasia, MN, RN, AOCN; Jennifer Filipi, MSN, NP
  • CE Released: 9/28/2022
  • Valid for credit through: 9/28/2023
Start Activity

  • Credits Available

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncology nurses and oncology nurse practitioners (NPs).

The goal of this activity is for learners to be better able to understand the role of PARP inhibitors in ovarian cancer and better able to care for patients with advanced ovarian cancer who are being treated with PARP inhibitors.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on PARP inhibitor therapy in patients with advanced ovarian cancer
  • Have greater competence related to
    • Identifying patients with advanced ovarian cancer eligible to receive PARP inhibitor therapy
    • Managing the toxicities associated with PARP inhibitor therapy in advanced ovarian cancer


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Paula Anastasia, MN, RN, AOCN

    Gynecological Oncology Clinical Nurse Specialist
    UCLA Health Sciences
    Los Angeles, California

    Disclosures

    Paula Anastasia, MN, RN, AOCN, has the following relevant financial relationships:
    Consultant or advisor for: Merck
    Speaker or member of speakers bureau for: Genentech (ended Dec 2021); Seagen Inc., formerly Seattle Genetics, Inc.

  • Jennifer Filipi, MSN, NP

    Nurse Practitioner, Gynecologic Oncology
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Disclosures

    Jennifer Filipi, MSN, NP, has no relevant financial relationships.

Editor

  • Christin Melton, ELS

    Associate Medical Education Director Medscape, LLC

    Disclosures

    Christin Melton, ELS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

The Nurse View: Incorporating PARP Inhibitor Therapy in Advanced Ovarian Cancer Management

Authors: Paula Anastasia, MN, RN, AOCN; Jennifer Filipi, MSN, NPFaculty and Disclosures

CE Released: 9/28/2022

Valid for credit through: 9/28/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand the role of PARP inhibitors in ovarian cancer and better able to care for patients with advanced ovarian cancer who are being treated with PARP inhibitors.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print